
AVE-9488
CAS No. 291756-32-6
AVE-9488( —— )
Catalog No. M34513 CAS No. 291756-32-6
AVE-9488 is a novel endothelial NO synthase (eNOS) enhancer that upregulates eNOS expression, induces NO production, and may ameliorate portal hypertension.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 445 | Get Quote |
![]() ![]() |
5MG | 686 | Get Quote |
![]() ![]() |
10MG | 938 | Get Quote |
![]() ![]() |
25MG | 1398 | Get Quote |
![]() ![]() |
50MG | 1822 | Get Quote |
![]() ![]() |
100MG | 2250 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameAVE-9488
-
NoteResearch use only, not for human use.
-
Brief DescriptionAVE-9488 is a novel endothelial NO synthase (eNOS) enhancer that upregulates eNOS expression, induces NO production, and may ameliorate portal hypertension.
-
DescriptionAVE-9488 is a novel endothelial NO synthase (eNOS) enhancer that upregulates eNOS expression, induces NO production, and may ameliorate portal hypertension.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetNOS
-
RecptorNOS | NO Synthase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number291756-32-6
-
Formula Weight255.29
-
Molecular FormulaC16H14FNO
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NC1CC=2C=CC=CC2C1)C3=CC=C(F)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
L-NMMA acetate
L-NMMA acetate is an inhibitor of nitric oxide synthase of all NOS isoforms (i.e. NOS1, NOS2, and NOS3).
-
Coniferaldehyde
Coniferaldehyde can significantly inhibit the growth of viability of strains of Oenococcus oeni. Coniferaldehyde exerts anti-inflammatory properties by inducing heme oxygenase-1(HO-1).
-
ETHYL CAFFEATE b
In vitro ECF suppressed the differentiation of naive CD4+ T cells into Th1. Furthermore ECF intensely blocked the transcriptional expression in interferon-γ-related signaling including IFN-γ T-bet STAT1 and STAT4.?